Back to results
US 8,278,305 B2Granted
Myosin light chain kinase inhibitor compounds, compositions and related methods of use
AssigneeNorthwestern University
InventorsDaniel Martin Watterson, Linda J. Van Eldik, Heather Behanna, Hantamalala Ralay Ranaivo
Life of this patent
Estimating the term…
Abstract
Pyridazinyl compounds, compositions and related methods of use.
Claims16
A method of inhibiting myosin light chain kinase activity, said method comprising:
- providing a medium comprising a myosin light chain kinase;
- and
- contacting said medium with a compound of a formula
- wherein R3 is selected from H and alkyl moieties;
- R6 is selected from H, halo, alkyl, aryl and heterocyclic moieties;
- n is an integer from 8 to 14;
- and X is (CH2)2Y, where Y is selected from substituted and unsubstituted pyrrolidinyl, substituted and unsubstituted pyrrolyl, substituted and unsubstituted pyrazolyl, substituted and unsubstituted imidazolyl and substituted and unsubstituted cyclopentyl moieties;
- and salts thereof, said compound in an amount sufficient to at least partially inhibit said kinase activity.
5 more elements
A method of treating progression of acute tissue injury, said method comprising:
- providing at least one of epithelial and endothelial tissue with barrier dysfunction, and
- contacting said tissue with a compound of a formula
- wherein R3 is selected from H and alkyl moieties;
- R6 is selected from H, halo, alkyl, aryl and heterocyclic moieties;
- n is an integer from 8 to 14;
- and X is (CH2)2Y, where Y is selected from substituted and unsubstituted pyrrolidinyl, substituted and unsubstituted pyrrolyl, substituted and unsubstituted pyrazolyl, substituted and unsubstituted imidazolyl and substituted and unsubstituted cyclopentyl moieties;
- and salts thereof, said compound in a therapeutically sufficient amount.
4 more elements
A method for selective kinase inhibition, said method comprising:
- providing a pyridazinylalkaneamide compound of a formula
- wherein R3 is selected from H and alkyl moieties;
- R6 is selected from H, halo, alkyl, aryl and heterocyclic moieties;
- n is an integer from 8 to 14;
- and X is (CH2)2Y, where Y is selected from substituted and unsubstituted pyrrolidinyl, substituted and unsubstituted pyrrolyl, substituted and unsubstituted pyrazolyl, substituted and unsubstituted imidazolyl and substituted and unsubstituted cyclopentyl moieties;
- and
- contacting said compound with a medium comprising a myosin light chain kinase, said compound in an amount sufficient to at least partially inhibit said kinase activity, said X moiety providing said compound inhibition activity selective over at least one of death-associated protein kinase, protein kinase A and protein kinase C.
4 more elements
Dependencies are inferred from the claim text.